

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 October 2025 (23.10.2025)



(10) International Publication Number
WO 2025/221338 A1

(51) International Patent Classification:

A61K 31/519 (2006.01) A61P 17/14 (2006.01)
C07D 487/04 (2006.01)

(21) International Application Number:

PCT/US2025/014609

(22) International Filing Date:

05 February 2025 (05.02.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/636,516	19 April 2024 (19.04.2024)	US
18/661,225	10 May 2024 (10.05.2024)	US

(71) Applicant: **SUN PHARMACEUTICAL INDUSTRIES, INC.** [US/US]; 2 Independence Way, Princeton, New Jersey 08540 (US).

(72) Inventor: **WIEDEMANN, Sean**; 11 Cutting Ln, Burlington, Massachusetts 01803 (US).

(74) Agent: **WARD, Robert D.** et al.; Medler Ferro Woodhouse & Mills PLLC, 8201 Greensboro Drive, Suite 1060, McLean, Virginia 22102 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: CRYSTALLINE FORM OF DEURUXOLITINIB




FIG. 1

(57) Abstract: The present disclosure is directed to polymorph Form 1 of 1*H*-pyrazole-1-propanenitrile, β -(cyclopentyl-2,2,3,3,4,4,5,5-*d*₈)-4-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)-, (β R)-, phosphate (1:1) (deuruxolitinib phosphate). Also disclosed are methods of treatment using polymorph Form 1 of deuruxolitinib phosphate and methods of making polymorph Form 1 of deuruxolitinib phosphate.



WO 2025/221338 A1